Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

Pfizer and Valneva's Lyme disease vaccine, VLA15, is under EMA review. It targets bacteria in ticks' guts, showing 70%+ efficacy in trials. Approval could take 12 months. Lyme disease is a significant but underreported infection in Europe, transmitted by ticks.

Valneva (VLS) stock rose 2.5% to €2.652 after releasing five-year data showing 94% of adults maintained antibody levels from a single dose of its chikungunya vaccine. The company expects continued monitoring for up to ten years. This follows a 5% surge yesterday on positive Phase 2 results for its Shigella vaccine candidate. The broader French market also gained 0.9%.

Valneva reports that its chikungunya vaccine, Ixchiq, maintains antibody levels for five years after a single dose in 94% of 221 healthy adults. The vaccine faced suspensions in the US and France due to adverse reactions, but the EU reinstated authorization in July 2025.

Valneva SE (VALN) shares rose 2% after reporting that 94% of participants maintained antibody response five years post a single dose of its chikungunya vaccine IXCHIQ. The study, involving 221 adults, showed consistent results across age groups. The company is also conducting real-world evidence studies, including a campaign in Brazil.

Valneva (VALN) reported that 94% of participants maintained antibody response five years after a single dose of its chikungunya vaccine, IXCHIQ. The company is gathering real-world data and monitoring participants for up to 10 years. IXCHIQ sales were EUR 4.4 million in H1 2026, down from EUR 7.5 million in H1 2025, following a U.S. license suspension.

Valneva SE reported that 94% of 221 adults maintained seroresponse five years after a single IXCHIQ vaccine dose, with comparable results in older and younger adults. The data supports IXCHIQ's durable antibody persistence, according to the company.